Clinical Trials Logo

Clinical Trial Summary

In this single-center, open-label, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. CD19 CAR T cells will be administered by i.v. injection as a using a "split dose" (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with chemotherapy resistant or refractory CD19+ ALL.


Clinical Trial Description

In this single-center, open-label, nonrandomized, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. Patients will be diagnosed according to morphologic, immunologic, cytogenetic and molecular(MICM) criteria, including bone marrow morphology, immunophenotype, cytogenetic and molecular examination. CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB,administered by i.v. injection as a using a "split dose" (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2. This protocol will be given to subjects with unmet medical needs for which there are no effective therapies known at this time. Side effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with chemotherapy resistant or refractory CD19+ ALL. ;


Study Design


Related Conditions & MeSH terms

  • Acute Lymphoblastic Leukaemia Recurrent
  • Acute Lymphoblastic Leukemia, Adult B-Cell
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT number NCT02975687
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital
Contact
Status Completed
Phase Phase 1
Start date November 2016
Completion date December 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05059847 - Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults N/A
Active, not recruiting NCT03709719 - Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia Phase 2
Active, not recruiting NCT04545333 - The clonoSEQ® Watch Registry
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT03984968 - CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1